Goldman Sachs Maintains Neutral on GeneDx Hldgs, Raises Price Target to $70
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs analyst Matthew Sykes maintains a Neutral rating on GeneDx Holdings (NASDAQ:WGS) but raises the price target from $54 to $70.
October 30, 2024 | 5:02 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Goldman Sachs has maintained a Neutral rating on GeneDx Holdings but increased the price target from $54 to $70, indicating a positive outlook despite the neutral stance.
The increase in the price target from $54 to $70 suggests that Goldman Sachs sees potential upside in GeneDx Holdings' stock, which could lead to a positive short-term impact on the stock price. However, the Neutral rating indicates that the analyst does not see a strong enough reason to recommend buying the stock, which tempers the potential impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100